Despite advances in understanding lung cancer over the past two decades ... where the effects of cancer-causing mutations are countered with drugs. For patients with early-stage NSCLC, targeted ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

One of the most exciting advances in the treatment of metastatic non-small-cell lung cancer (NSCLC ... for patients who have ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

[10] Targeted therapies for cancer tend to be most effective when the therapeutic compound inhibits a pathway that is constitutively activated during the early stages of tumor development ...

FDA approved for the treatment of metastatic melanoma harboring activating BRAF mutations in August, 2011. Vemurafenib is metabolized by cytochrome P450 isoenzymes (predominantly CYP3A4 ...

The AI-driven tools are getting better at recommending biomarker-targeted therapies, but experts warn they aren't ready for prime time.

For example, certain mutations are more common in people who smoke who develop lung cancer, while other mutations are often seen in never-smokers who develop the disease. Somatic gene mutations ...

More than 150,000 people are diagnosed with colorectal cancer each year, making it the fourth most common cancer in the U.S., according to the National Cancer Institute. BRAF mutations occur in ...

Knowing what mutations caused the tumor may help doctors recommend targeted therapy for lung cancer if available for the type of tumor markers a person’s cancer has. Tumor markers may be helpful ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval — boosting an oncology portfolio Pfizer is looking to for revenue growth.